Impact of the epidermal growth factor receptor mutation status on the prognosis of recurrent adenocarcinoma of the lung after curative surgery
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Impact of the epidermal growth factor receptor mutation status on the prognosis of recurrent adenocarcinoma of the lung after curative surgery
Authors
Keywords
-
Journal
BMC CANCER
Volume 18, Issue 1, Pages -
Publisher
Springer Nature America, Inc
Online
2018-10-05
DOI
10.1186/s12885-018-4849-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Prognostic impacts of EGFR mutation status and subtype in patients with surgically resected lung adenocarcinoma
- (2017) Kazuya Takamochi et al. JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY
- Clinical and pathological characteristics of EGFR mutation in operable early-stage lung adenocarcinoma
- (2017) Masaya Yotsukura et al. LUNG CANCER
- Epidermal Growth Factor Receptor Mutations and Prognosis in Pathologic N1-N2 Pulmonary Adenocarcinoma
- (2016) Tetsuya Isaka et al. ANNALS OF THORACIC SURGERY
- Postoperative follow-up strategy based on recurrence dynamics for non-small-cell lung cancer
- (2016) Katsuya Watanabe et al. EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY
- Epidermal growth factor receptor-tyrosine kinase inhibitor therapy is especially beneficial to patients with exon 19 deletion compared with exon 21 L858R mutation in non-small-cell lung cancer: Systematic review and meta analysis
- (2016) Yinghui Liu et al. Thoracic Cancer
- Epidermal growth factor receptor gene mutation as risk factor for recurrence in patients with surgically resected lung adenocarcinoma: a matched-pair analysis
- (2016) Yuki Matsumura et al. Interactive Cardiovascular and Thoracic Surgery
- Exon 19 deletion was associated with better survival outcomes in advanced lung adenocarcinoma with mutant EGFR treated with EGFR-TKIs as second-line therapy after first-line chemotherapy: a retrospective analysis of 128 patients
- (2015) Y. Wang et al. Clinical & Translational Oncology
- Gefitinib treatment in patients with postoperative recurrent non-small-cell lung cancer harboring epidermal growth factor receptor gene mutations
- (2015) Yuhei Yokoyama et al. International Journal of Clinical Oncology
- Correlations Between the EGFR Mutation Status and Clinicopathological Features of Clinical Stage I Lung Adenocarcinoma
- (2015) Tetsuya Isaka et al. MEDICINE
- The Correlation of the International Association for the Study of Lung Cancer (IASLC)/American Thoracic Society (ATS)/European Respiratory Society (ERS) Classification With Prognosis and EGFR Mutation in Lung Adenocarcinoma
- (2014) Naoki Yanagawa et al. ANNALS OF THORACIC SURGERY
- Relationships between EGFR Mutation Status of Lung Cancer and Preoperative Factors - Are they Predictive?
- (2014) Katsuo Usuda et al. Asian Pacific Journal of Cancer Prevention
- Clinicopathological features and EGFR gene mutation status in elderly patients with resected non–small-cell lung cancer
- (2014) Teppei Nishii et al. BMC CANCER
- The effect of gefitinib in patients with postoperative recurrent non-small cell lung cancer harboring mutations of the epidermal growth factor receptor
- (2014) Ryo Ko et al. International Journal of Clinical Oncology
- Role of lymphatic invasion in the prognosis of patients with clinical node-negative and pathologic node-positive lung adenocarcinoma
- (2014) Takahiro Mimae et al. JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY
- Epidermal Growth Factor Receptor Mutations: Effect on Volume Doubling Time of Non–Small-Cell Lung Cancer Patients
- (2014) Ryota Nakamura et al. Journal of Thoracic Oncology
- Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
- (2014) Yi-Long Wu et al. LANCET ONCOLOGY
- Patients with Exon 19 Deletion Were Associated with Longer Progression-Free Survival Compared to Those with L858R Mutation after First-Line EGFR-TKIs for Advanced Non-Small Cell Lung Cancer: A Meta-Analysis
- (2014) Yaxiong Zhang et al. PLoS One
- Validation of the IASLC/ATS/ERS Lung Adenocarcinoma Classification for Prognosis and Association with EGFR and KRAS Gene Mutations: Analysis of 440 Japanese Patients
- (2012) Akihiko Yoshizawa et al. Journal of Thoracic Oncology
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
- (2012) Rafael Rosell et al. LANCET ONCOLOGY
- Clinical Significance and Role of Lymphatic Vessel Invasion as a Major Prognostic Implication in Non-Small Cell Lung Cancer: A Meta-Analysis
- (2012) Jun Wang et al. PLoS One
- Effect of gefitinib on the survival of patients with recurrence of lung adenocarcinoma after surgery: A retrospective case-matching cohort study
- (2010) Tatsuya Katayama et al. SURGICAL ONCOLOGY-OXFORD
- Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
- (2009) Tetsuya Mitsudomi et al. LANCET ONCOLOGY
- Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
- (2009) Rafael Rosell et al. NEW ENGLAND JOURNAL OF MEDICINE
- Better survival with EGFR exon 19 than exon 21 mutations in gefitinib-treated non-small cell lung cancer patients is due to differential inhibition of downstream signals
- (2008) Jian-quan Zhu et al. CANCER LETTERS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started